TrialArthritis and rheumatism2009

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Daniel J Wallace et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.